Drugs / TNG348
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06065059 | Dec 2023 → May 2024 | BRCA1-related cancer predisposition, hereditary breast carcinoma, malignant pancreatic neoplasm, ovarian carcinoma +1 | Tango Therapeutics, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-05-23 | Medivir | Results Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program medivir.com ↗
Medivir’s licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts. |
| 2023-09-11 | Medivir | Regulatory Medivir´s Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study medivir.com ↗
Medivir’s partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNG348 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06065059 ↗ |
| Action | Inhibit | “Ubiquitin Specific Peptidase 1 (USP1) inhibitor” NCT06065059 ↗ |
| Target | USP1 | “Ubiquitin Specific Peptidase 1 (USP1) inhibitor” NCT06065059 ↗ |